Evonile Pharma Board Approves ₹900 Crore Partly Paid Rights Issue

Board approved rights issue of partly paid Rs 5 shares up to Rs 900 Cr to eligible holders on record date, subject to approvals. Set up issue panel, approved postal ballot notice, new website. First equity raise since listing under new control; prior growth self-funded before recent shift to debt for large brand buy. Marks turn to dilution-led refinancing and formalizes new identity. Turns cash-rich self-funded profile to dilution-led growth; price, ratio, record date, timetable and use of proceeds undisclosed. Postal ballot purpose, formal name approvals pending.